Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 93

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 93
---
ing Statements Certain statements in this proxy statement/prospectus may constitute “forward -lookingstatements” for purposes of the federal securities laws. Our forward -lookingstatements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward -lookingstatements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward -lookingstatements, but the absence of these words does not mean that a statement is not forward -looking. Forward -lookingstatements in this proxy statement/prospectus may include, for example, statements about: •our ability to consummate the Business Combination; •the benefits of the Business Combination; •the Combined Company’s financial performance following the Business Combination; •the ability to obtain or maintain the listing of the Company Shares or Company Warrants on Nasdaq, following the Business Combination; •changes in the Company’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; •the Company’s ability to develop and launch new products and services; •the Company’s ability to successfully and efficiently integrate future expansion plans and opportunities; •the Company’s ability to obtain regulatory approvals for tests; •the rate and degree of market acceptance of the Company’s tests and genetic testing generally; •the Company’s expectations regarding the Company’s platform and future offerings; •the timing and results of studies with respect to the Company’s tests; •the Company’s ability to grow its business in a cost -effectivemanner; •the degree to which individuals will share genetic information with the Company; •the Company’s use of technology and ability to prevent security breaches; •the Company’s ability to remain competitive, particularly if the testing markets continue to expand, and competition becomes more acute; •the Company’s ability to obtain and maintain protection of its trade secrets, licensed intellectual property, patents, and other intellectual property rights and to not infringe the rights of others; •the risks that uncertainty and instability resulting from ongoing conflicts, including the conflict between Russia and Ukraine, could adversely affect the Company’s business, financial condition and operations, in addition to global macroeconomic indications